Strategies for Supporting Early Diagnosis and Implementation of Amyloid-Targeting Therapies in Alzheimer Disease : Episode 10
Opinion
Video
Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
Panelists discuss how ideal candidates for amyloid-targeting therapy typically present with biomarker-confirmed early-stage Alzheimer disease, demonstrate positive amyloid PET scans or CSF biomarkers, exhibit mild cognitive impairment or mild dementia, lack contraindications such as significant cerebrovascular disease or anticoagulant use, have adequate support systems for monitoring and managing potential adverse effects, and would benefit from comprehensive pretreatment evaluations including brain MRI and APOE genotyping.
Video content above is prompted by the following:
- Could you describe the profile of a patient who would be a candidate for treatment with amyloid-targeting therapy?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
